Subcutaneous vs Intravenous Heparin in the Treatment of Deep Venous Thrombosis – A Randomized Clinical Trial

Summary

271 patients with acute symptomatic deep venous thrombosis of lower limbs, confirmed by strain-gauge plethysmography and/ or venography, were randomly assigned to receive intermittent subcutaneous heparin calcium or heparin sodium by continuous intravenous infusion for 6–10 days. Heparin dosage was adjusted to maintain activated partial thromboplastin time values (Throm-bofax reagent) at 1.3–1.9 times the basal ones. Strain-gauge plethysmography was repeated at the end of heparin treatment, and evaluation of therapy was performed by comparing the indexes of venous hemodynamics and by assessing the incidence of pulmonary embolism and of bleeding complications.

In the intravenous group, Maximal Venous Outflow (MVO) increased from 20.8 ± 12.8 to 28.4 ± 17.5 ml/min per 100 ml of tissue and Venous Capacitance (VC) from 1.39 ± 0.92 to 1.94 ± 1.0 ml/100 ml of tissue (mean ± SD). In the subcutaneous group, MVO increased from 21.0 ± 12.7 to 27.5 ± 18.1 and VC from 1.60 ± 0.86 to 2.06 ± 1.0. The median improvement of MVO and VC were 22% and 36% respectively in the IV group and 20% and 24% in the SC group. Clinical pulmonary embolism occurred in 2 patients in the intravenous group (1 fatal) and in 4 in the subcutaneous group (1 fatal). 9 major bleeding complications occurred in the intravenous group (1 fatal) and 5 in the subcutaneous group (1 fatal). The differences were not significant at the statistical analysis.

The results suggest that subcutaneous intermittent heparin has a comparable efficacy to continuous intravenous heparin in the treatment of deep venous thrombosis.

To the same conclusion points an overview of the seven randomized trials which compared these treatment modalities.

• References

• 1 Lagerstedt CI, Olsson CG, Fagher BO, Öqvist BW, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; II: 515-518
• 2 Salzman EW, Deykin D, Shapiro RM. The management of heparin therapy. Controlled prospective trial. N Engl J Med 1975; 292: 1046-1050
• 3 Glazier RL, Crowell EB. Randomised prospective trial of continuous vs intermittent heparin therapy. JAMA 1976; 236: 1365-1367
• 4 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thromb Res 1982; 27: 631-639
• 5 Doyle DJ, Turpie A GG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep-vein thrombosis. Ann Intern Med 1987; 107: 441-445
• 6 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenblum D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114
• 7 Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177-187
• 8 Walker MG, Shaw JW, Thomson G JL, Cumming J GR, Lea ThomasM. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep-vein thrombosis of the legs: a multicentre prospective randomised trial. Br Med J 1987; 294: 1189-1192
• 9 Pini M, PotÍ R, Poli T, Tagliaferri R, Dettori AG. Accuracy of strain-gauge plethysmography as a diagnostic test in clinically suspected deep venous thrombosis. Thromb Res 1984; 35: 149-157
• 10 Krahenbuehl B, Simon CA, Bouvier CA, Schinas P, Hopf MA, Cochet B. Traitement heparinique. Comparaison entre les voies d’admistration intraveineuse et souscutanee. Schweiz Med Wschr 1979; 109: 1322-1325
• 11 Pini M, Manotti C, Pattacini C, Megha A, Dettori AG. Antithrombin III kinetics during and after subcutaneous or intravenous heparin treatment in patients with deep venous thrombosis. Thromb Haemo-stas 1985; 54: 89 (Abstr)
• 12 Pini M, Megha A, Pattacini C, PotÍ R, Quintavalla R, Tagliaferri A. Variazioni delFantitrombina III in rapporto con la terapia eparinica perfusionale o sottocutanea in pazienti con trombosi venosa profonda. In: Tesi M. et al. (ed) Progressi in Flebologia Minerva Medica Publishers; Torino: 1986: 194-198
• 13 Green PJ. Antithrombin III and subcutaneous heparin. Lancet 1980; I: 374-375
• 14 Conard J, Lecompte T, Horellou HM, Cazenave B, Samama M. Antithrombin III in patients treated with subcutaneous or intravenous heparin. Thromb Res 1981; 22: 507-511
• 15 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Wilhelmsson S. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-340